article
10 June 2020 | By Emma Cummins - Centre for Drug Research and Development Canada, Gregorio Aversa - Abimmune Technologies Inc., Ismael Samudio - Centre for Drug Research and Development Canada
As the number of antibody discovery platforms and formats expands, various characteristics must be rigorously screened for and taken into consideration when deciding which hits to progress to successful development. The earlier in the antibody discovery pathway the assessment is carried out, the greater the hit enrichment and selection will…